GoAI
Get started
Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc.

FENC

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$11.29

−$0.06 · -0.53%

Aug 21, 4:00 PM ET

FENC company overview

Historical prices · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

56

Fair Value

Momentum

67

Gaining

Sentiment

64

Bullish

Risk resilience

56

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $11.29

52-week range

Current $11.29

Open
$11.43
Previous close
$11.35
Volume
210.74K
Market cap
392.18M USD
50-day average
$10.4911
+7.62% above average
200-day average
$8.4342
+33.86% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
183.32M USD
P/E (TTM)
-86.85×
P/B (TTM)
9.19×
P/S (TTM)
6.62×
EV / EBITDA
-24.6×
Earnings yield
-4.43%
Free cash flow yield
-5.67%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
93.73%
Operating margin
-1.96%
Net margin
-5.49%
Return on equity
-27.79%
Return on assets
-13.90%
Return on invested capital
-10.65%

Financial health

Debt / equity
0×
Current ratio
6.34×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends258%-397%-1053%-1709%Gross margin, FY2022: 94.40%Gross margin, FY2023: 94.08%Gross margin, FY2024: 93.30%Gross margin, FY2025: 91.57%Operating margin, FY2022: -1481.30%Operating margin, FY2023: -61.44%Operating margin, FY2024: 5.21%Operating margin, FY2025: -14.22%Net margin, FY2022: -1544.89%Net margin, FY2023: -75.50%Net margin, FY2024: -0.92%Net margin, FY2025: -21.82%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 94.40%. Gross margin FY2023 94.08%. Gross margin FY2024 93.30%. Gross margin FY2025 91.57%. Operating margin FY2022 -1481.30%. Operating margin FY2023 -61.44%. Operating margin FY2024 5.21%. Operating margin FY2025 -14.22%. Net margin FY2022 -1544.89%. Net margin FY2023 -75.50%. Net margin FY2024 -0.92%. Net margin FY2025 -21.82%.

Income trends

Revenue

44.64M USD-6.09%

Operating income

−6.35M USD−8.83M USD

Net income

−9.74M USD-2134.17%
Income trends across reported periods54.66M USD26.16M USD−2.34M USD−30.84M USDRevenue, FY2022: 1.54M USDRevenue, FY2023: 21.25M USDRevenue, FY2024: 47.54M USDRevenue, FY2025: 44.64M USDOperating income, FY2021: −17.22M USDOperating income, FY2022: −22.74M USDOperating income, FY2023: −13.06M USDOperating income, FY2024: 2.48M USDOperating income, FY2025: −6.35M USDNet income, FY2021: −17.35M USDNet income, FY2022: −23.71M USDNet income, FY2023: −16.05M USDNet income, FY2024: −436K USDNet income, FY2025: −9.74M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 1.54M USD. Revenue FY2023 21.25M USD. Revenue FY2024 47.54M USD. Revenue FY2025 44.64M USD. Operating income FY2021 −17.22M USD. Operating income FY2022 −22.74M USD. Operating income FY2023 −13.06M USD. Operating income FY2024 2.48M USD. Operating income FY2025 −6.35M USD. Net income FY2021 −17.35M USD. Net income FY2022 −23.71M USD. Net income FY2023 −16.05M USD. Net income FY2024 −436K USD. Net income FY2025 −9.74M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue44.64M USD47.54M USD21.25M USD1.54M USD—
Cost of goods sold3.76M USD3.18M USD1.26M USD86K USD—
Gross profit40.88M USD44.35M USD19.99M USD1.45M USD—
Research and development250K USD307K USD56K USD3.53M USD4.98M USD
Selling, general, and administrative46.91M USD41.48M USD32.71M USD20.51M USD12.24M USD
Operating expenses47.22M USD41.88M USD33.05M USD24.19M USD17.22M USD
Interest income787K USD1.59M USD441K USD195K USD54K USD
Interest expense2.08M USD4.07M USD3.39M USD978K USD126K USD
Depreciation and amortization103K USD800K USD287K USD149K USD16K USD
Operating income−6.35M USD2.48M USD−13.06M USD−22.74M USD−17.22M USD
Net income−9.74M USD−436K USD−16.05M USD−23.71M USD−17.35M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-112.10%
11 comparable reports
Latest EPS result
0.05
Estimate 0.02 · Beat by 150.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.620.340.05-0.23Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 10, 2025: actual -0.06, estimate 0.56, surprise -110.71%, Miss. Q2 2025, reported May 13, 2025: actual -0.04, estimate -0.12, surprise +66.67%, Beat. Q3 2025, reported Aug 14, 2025: actual -0.11, estimate -0.06, surprise -83.33%, Miss. Q4 2025, reported Nov 13, 2025: actual -0.02, estimate -0.08, surprise +75.00%, Beat. Q1 2026, reported Mar 24, 2026: actual -0.17, estimate 0.03, surprise -666.67%, Miss. Q2 2026, reported May 14, 2026: actual 0.01, estimate -0.02, surprise +150.00%, Beat. Q3 2026, reported Aug 11, 2026: actual 0.05, estimate 0.02, surprise +150.00%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 0.1, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates20.12M15.71M11.3M6.89MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 10, 2025: actual 7.93M USD, estimate 7.8M USD, surprise +1.59%, Beat. Q2 2025, reported May 13, 2025: actual 8.75M USD, estimate 9.04M USD, surprise -3.23%, Miss. Q3 2025, reported Aug 14, 2025: actual 9.65M USD, estimate 9.56M USD, surprise +0.94%, Beat. Q4 2025, reported Nov 13, 2025: actual 12.46M USD, estimate 14.69M USD, surprise -15.16%, Miss. Q1 2026, reported Mar 24, 2026: actual 13.78M USD, estimate 14.73M USD, surprise -6.49%, Miss. Q2 2026, reported May 14, 2026: actual 15.1M USD, estimate 13.9M USD, surprise +8.64%, Beat. Q3 2026, reported Aug 11, 2026: actual 17.87M USD, estimate 16.21M USD, surprise +10.29%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 19.21M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$16.00

41.72% upside
Past 12 months12-month forecastHigh $16.00Average $16.00Low $16.00

Rating distribution

8 ratings
Strong buy00%
Buy8100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

4 institutions
B. Riley SecuritiesmaintainBuy

FENC news

zacks.com

Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in…

Read source
seekingalpha.com

Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Adherex Technologies Q2 Earnings Call Highlights

Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its…

Read source
zacks.com

Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates

Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.11 per share a year ago.

Read source
globenewswire.com

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its…

Read source
defenseworld.net

Adherex Technologies Inc. (NASDAQ:FENC) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the company, MarketBeat reports. One…

Read source

Corporate actions

Corporate action history

Stock split

Effective Sep 9, 2014

1:3

Stock split

Effective Aug 31, 2011

1:18

Stock split

Effective Aug 2, 2005

1:5

FENC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding FENC

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
7.8M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.56M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
304.56K
Weight
0.02%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$282.73+1.21%
Global X - Russell 2000 ETF logoGlobal X - Russell 2000 ETFRSSL
Market value
155.81K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.08%
Price / 1D
$117.49+0.86%
Vanguard Russell 3000 ETF logoVanguard Russell 3000 ETFVTHR
Market value
20.05K
Weight
0.00%
AUM
6.1B USD
Expense ratio
0.06%
Price / 1D
$338.91+0.49%
ProShares - UltraPro Russell2000 logoProShares - UltraPro Russell2000URTY
Market value
13.31K
Weight
0.00%
AUM
340.71M USD
Expense ratio
1.08%
Price / 1D
$85.08+2.19%
ProShares - Ultra Russell2000 logoProShares - Ultra Russell2000UWM
Market value
10.23K
Weight
0.00%
AUM
255.73M USD
Expense ratio
1.07%
Price / 1D
$66.34+1.47%
ProShares - Hedge Replication ETF logoProShares - Hedge Replication ETFHDG
Market value
270.96
Weight
0.00%
AUM
22.26M USD
Expense ratio
0.95%
Price / 1D
$55.0199+0.25%

Continue in GoAI

Research FENC

research.disclaimer